Entreprises
Uber Eats adds over 375 Wakefern supermarkets to platform
Uber Eats expands its grocery delivery service by adding more than 375 Wakefern Food Corp. supermarket locations across the Northeast, offering up to 30% off first orders and free delivery for Uber One members.
TUI Exits Castelfalfi After $350 Million Investment; New Owners Target Luxury Resort
German travel giant TUI sold its Tuscany resort to the family of Indorama founder Sri Prakash Lohia after failing to achieve takeoff despite years of investment. The property reopened in 2024 under new management.
Swiss Hotel Overnight Stays Fall 2.1% in August as Heat Drives Mountain Traffic
Swiss hotels saw a 2.1% drop in August overnight stays vs. year-ago, BFS data shows, with mountain regions buoyed by heat-seeking domestic travelers while cities falter on weak Gulf and Asian demand.
Tempus AI Sets 25% Growth Target as Assay Pricing, M&A Drive Outlook
CEO Eric Lefkofsky outlined sustained growth ambitions, major assay price increases, and the Personalis acquisition at the Morgan Stanley healthcare conference.
REGENXBIO Seeks FDA Approval for Duchenne Therapy; Cash Runs Into Late 2027
Gene-therapy company reported $313 million in pro forma cash at its September 2026 conference presentation, covering operations through Q4 2027 as it awaits PDUFA decision on RGX-202.
GT Biopharma gets FDA clearance for multiple myeloma trial of GTB-5550
The oncology company received investigator-sponsored trial clearance for its B7-H3-targeted TriKE therapy, contingent on non-dilutive grant funding.
Genmab Pipeline Widens With Colorectal Expansion, Data Readouts Loom
Biotech's market cap stands at $19.5 billion as Phase III data for petosemtamab, EPKINLY and Rina-S are expected in late 2024, with colorectal expansion opening a market three times larger than its head-and-neck indication.
Recursion Pharmaceuticals Shifts From Platform Promise to Clinical-Stage Drug Developer
At the Morgan Stanley Healthcare Conference, Recursion Pharmaceuticals detailed how its AI-driven drug discovery engine has moved into clinical-stage development, outlining pipeline milestones, partnership returns, and cost restructuring after the Exscientia integration.
Macy's Raises Full-Year EPS View to $2.15-$2.35 as 'A Bold New Chapter' Strategy Accelerates
The retailer lifted its full-year earnings per share guide and highlighted sustained sales growth, pointing to two and a half years of progress under its transformation strategy at the Goldman Sachs conference.
Belite Bio's Tinlarebant Approaches FDA Decision After Strong Trial Data
Belite Bio expects FDA review of tinlarebant by February 2025, as clinical data showed 35.7% reduction in retinal lesion growth in the DRAGON trial for Stargardt disease.
Kennametal unveils KAF82 tungsten carbide grade for additive tooling
Kennametal introduced KAF82, a tungsten‑carbide powder for additive manufacturing of custom hole‑finishing tools, now available exclusively to its customers.
HealthStream Raises $40M From Copart Founder Willis Johnson in Private Placement
HealthStream Inc. completed a $40 million private placement led by Willis Johnson, who founded Copart, as CEO Robert Frist remains the company's largest shareholder.
Xometry Expands TradeCentric Partnership to Add Purchase Order and Invoice Automation
The expanded integration connects Xometry’s manufacturing marketplace with over 220 eProcurement platforms, aiming to streamline ordering and invoicing for enterprise buyers.
Fortinet Opens $60 Million Innovation Hub in New York City
The cybersecurity company is expanding its physical footprint in NYC with a 40,000-square-foot facility featuring a data center, training center, and executive briefing space.
Vertical Data Signs LOI for $192 Million GPU Cluster Deployment
The OTCQB-listed firm said it has agreed to supply 1,024 NVIDIA B300 Blackwell Ultra GPUs in a single-tenant cluster to an unnamed global AI developer, with service slated to start in Q1 2027.
Credo Launches 224G ZeroFlap Optical Transceivers for AI Networks
Credo Technology Group unveiled its 224G ZeroFlap optical transceiver family, extending its reliability architecture to 1.6T port speeds for AI data centers. Cignal AI forecasts over 11 million units shipping in 2026, more than double in 2027.
Cloudastructure partners with SAGE Integration to sell AI surveillance in US
Cloudastructure announced a non‑exclusive reseller agreement with SAGE Integration, giving the integrator access to its AI video‑surveillance platform across 62 U.S. metros and 20 countries.
RGA Sees Selective Growth, $2B Capital Buffer at Barclays Conference
Reinsurance Group of America outlined its capital deployment strategy and growth targets at the Barclays conference, pointing to a $44B in-force embedded value and a pace of earnings expansion of 8%-10%.
Wells Fargo Outlines Growth Broadens at Barclays Global Financial Services Conference
CFO Mike Santomassimo discussed loan growth, net interest income guidance, expense targets and a new tokenized deposit product set for production next week.
KKR's Private Credit Platform Swells to $300 Billion at Barclays Conference
KKR's credit AUM reaches $300 billion, with private credit at $141 billion, as co-head Chris Sheldon highlights a $6 trillion financing gap in hyperscaler CapEx and rising demand in Asia.
Alliant Credit Union Taps Blend for Digital Mortgage Lending Platform
Chicago-based credit union with nearly 1 million members and $20 billion in assets partners with Blend Labs to digitize home lending and shorten HELOC closing timelines to 15 days or less.
Fate Therapeutics Highlights FT819 Lupus Trial Progress in Phase 1 Study
Data from 16 SLE patients showed early improvements in disease activity and nephritis, with no Grade 3 cytokine release syndrome or dose-limiting toxicities in Regimen A.
Rezolute Seeks FDA Feedback After Mixed HI Trial Readout
Rezolute is awaiting FDA review of supplemental data showing CGM-based glycemic improvements after its Phase 3 primary endpoint was missed.
Cocrystal Pharma Completes Dosing in Phase 1b Norovirus Drug Trial
The company announced that the last subject has been dosed in a randomized, double-blind, placebo-controlled Phase 1b challenge study of its oral antiviral CDI-988 at Emory University. Preliminary efficacy results are expected in late 2026 or early 2027, with no serious adverse events reported to date.